Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 17, 2024
Implantation Mycoses in Immunocompromised Patients: a retrospective review of disease course and treatment efficacy
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 13, 2025
A prospective, multicenter, single-arm, non-randomized clinical study designed to evaluate the safety and effectiveness of the Citadel Embolization Device
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 24, 2025
Efficacy of Luspatercept In Clonal Cytopenias of Uncertain Significance
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 27, 2025
A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 27, 2025
A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 26, 2025
Boomerang-Pivotal Multicenter Trial of the Boomerang Catheter for Percutaneous Deep Vein Arterialization (pDVA)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2025
Serranator OCT: Understanding the Mechanism of Action of Serration Angioplasty by Serranator Versus Conventional Balloon Angioplasty for below-the Knee (BTK) Artery Disease Using Optical Coherence Tomography (OCT)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2025
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab in Combination With Pola-R-CHP Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 22, 2025
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2025